Details of the Drug Combination

General Information of Drug Combination (ID: DC5L4VT)

Drug Combination Name
Cabazitaxel SY-1425
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs Cabazitaxel   DMPAZHC SY-1425   DMH8UF0
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: HS 578T
Zero Interaction Potency (ZIP) Score: 25.7
Bliss Independence Score: 18.62
Loewe Additivity Score: 15.14
LHighest Single Agent (HSA) Score: 21.96

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cabazitaxel
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Metastatic prostate carcinoma N.A. Investigative [3]
Cabazitaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [5]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [6]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Affects Expression [7]
Proline-rich AKT1 substrate 1 (AKT1S1) OT4JHN4Y AKTS1_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [4]
Myelodysplastic syndrome 2A37 Phase 1 [4]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCX1XS1 DU-145 Investigative [8]
Adenocarcinoma DCF5CKV A549 Investigative [8]
Adenocarcinoma DCL69GJ HT29 Investigative [8]
Adult acute myeloid leukemia DCVDJ6Q HL-60(TB) Investigative [8]
Childhood T acute lymphoblastic leukemia DCDXUEZ CCRF-CEM Investigative [8]
Chronic myelogenous leukemia DC7P54Z K-562 Investigative [8]
Clear cell renal cell carcinoma DC5UWNF CAKI-1 Investigative [8]
Cutaneous melanoma DCSJYHZ SK-MEL-5 Investigative [8]
Glioma DCUYL3N SF-539 Investigative [8]
Large cell lung carcinoma DC3JC4U NCI-H460 Investigative [8]
Lung adenocarcinoma DC3HIHL NCI-H522 Investigative [8]
Malignant melanoma DCD82CM UACC62 Investigative [8]
Malignant melanoma DCK05N1 LOX IMVI Investigative [8]
Melanoma DC8AXGT MALME-3M Investigative [8]
Mixed endometrioid and clear cell carcinoma DCLT4H1 IGROV1 Investigative [8]
Papillary renal cell carcinoma DCQS69I ACHN Investigative [8]
Plasma cell myeloma DC0EZ50 RPMI-8226 Investigative [8]
Pleural epithelioid mesothelioma DC8VA2B NCI-H226 Investigative [8]
Renal cell carcinoma DC4IIU3 SN12C Investigative [8]
Breast adenocarcinoma DCBKMGH MDA-MB-468 Investigative [1]
Carcinoma DCEOQSM RXF 393 Investigative [1]
Carcinoma DCBG3DV MCF7 Investigative [1]
Invasive ductal carcinoma DC7KOX2 T-47D Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
3 Cabazitaxel FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
7 The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966